During the pandemic, it is more important than ever that we work together to flatten the curve. At the CTN, we are proud to be a conduit for the rapid implementation of national co-ordinated COVID-19 trials. Our team of experts are mobilized to help researchers turn a good idea into great research.
The CTN is a collaborative network committed to generating knowledge on the prevention, treatment, and management of HIV, hepatitis C, and other sexually transmitted and blood-borne infections (STBBIs) through the conduct of scientifically sound clinical trials, research, and other interventions.
Led by National Director Dr. Aslam Anis, with National Co-Directors Drs. Sharon Walmsley and Marina Klein, the CTN is dedicated to engaging with the community, maximizing the impact of research, and ultimately improving the health of Canadians.
The CTN supports clinical trials of the highest scientific standards. Each trial has been approved by the Network’s Community Advisory Committee and Scientific Review Committee, or other national peer-review panels.
Do you have a great concept for a research project? It is important to understand and plan all required study activities as early as possible.
Learn More
Guidelines for patient care help to support the use of best practices by clinicians, community members, and policy makers.
Learn MoreThe CTN is committed to maximizing the impact of research to improve the health of Canadians by applying knowledge gained through research at home and abroad into applications and practice.
Aging is a complex and poorly understood process. The interaction between HIV and aging increases this complexity and presents a unique set of challenges.
Learn More
Response to the HIV epidemic now includes elimination of other sexually transmitted and blood-borne infections (STBBIs), such as syphilis and gonorrhea.
Learn More
Research in targeted immunotherapies, vaccines, and emerging areas of research in treatment, immune system support, and cure.
Learn More
CTN-supported guidelines for patient care help to support the use of best practices by clinicians, community members, and policy makers.
Learn More
The WHO-funded study shows that dolutegravir is the optimal choice for first-line treatment of HIV
Learn More
Discover more about a selection of the 2020/21 Postdoctoral Fellow presentations, which will be taking place at the virtual CTN Fall Meetings on October 21, 2020
Learn More
Since 1993, the CTN Community Advisory Committee (CAC) has changed the course of HIV research in Canada. Let’s meet four new members who joined the CAC in 2020
Learn MoreThrough CTN-supported studies, our Investigators have produced hundreds of peer-reviewed publications in a wide range of HIV- and STBBI-related areas.
